SCHEMBL18066

SCHEMBL18066

Cn1cnc(C=O)c1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6498246 0.78
SCHEMBL608314 0.76
SCHEMBL27705444 0.74
SCHEMBL18734285 0.74
SCHEMBL12229581 0.73 HDAC1 (0.37)
SCHEMBL27887198 0.73
SCHEMBL3910931 0.73 KDM5A (0.41)
SCHEMBL2926647 0.72 CYP2E1 (0.38)
SCHEMBL20306728 0.71
SCHEMBL16704705 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 530 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119570222-A Degradable composite film paper material and preparation method thereof 广东道科新材料科技有限公司 2025-03-07 CN claimed
US-11668708-B2 Method for reducing measurement error in latex agglutination immunoassay SEKISUI MEDICAL CO., LTD. (JP) 2023-06-06 US claimed
CN-112635804-A Alkaline anion exchange membrane for fuel cell and preparation method thereof 安徽知凸凸科技服务有限公司 2021-04-09 CN claimed
CN-107667097-B Separation of enantiomers of 3-ethylbicyclo [3.2.0] hept-3-en-6-one 诺瓦色生物公司 2021-02-12 CN claimed
EP-3303308-B1 SEPARATION OF ENANTIOMERS OF 3-ETHYLBICYCLO[3.2.0]HEPT-3-EN-6-ONE NOVASSAY SA (CH) 2019-10-09 EP claimed
US-10150723-B2 Separation of enantiomers of 3-ethylbicyclo[3.2.0]hept-3-en-6-one NOVASSAY S.A. (CH) 2018-12-11 US claimed
US-20180134643-A1 SEPARATION OF ENANTIOMERS OF 3-ETHYLBICYCLO[3.2.0]HEPT-3-EN-6-ONE NOVASSAY S.A. (CH) 2018-05-17 US claimed
EP-3303308-A1 SEPARATION OF ENANTIOMERS OF 3-ETHYLBICYCLO[3.2.0]HEPT-3-EN-6-ONE Novassay SA (CH) 2018-04-11 EP claimed
WO-2016146299-A1 SEPARATION OF ENANTIOMERS OF 3-ETHYLBICYCLO[3.2.0]HEPT-3-EN-6-ONE NOVASSAY SA (CH) 2016-09-22 WO claimed
EP-1817036-B1 MODULATORS OF MUSCARINIC RECEPTORS VERTEX PHARMA (US) 2012-07-04 EP claimed
EP-4724437-A1 METHODS OF TREATING INFLAMMATORY DISEASES Interline Therapeutics, Inc. (US) 2026-04-15 EP disclosed
US-20260091026-A1 METHODS OF TREATING INFLAMMATORY DISEASES INTERLINE THERAPEUTICS INC (US) 2026-04-02 US disclosed
US-12465643-B2 Ras inhibitors Revolution Medicines, Inc. (US) 2025-11-11 US disclosed
US-20250319187-A1 RAS INHIBITORS REVOLUTION MEDICINES INC (US) 2025-10-16 US disclosed
US-20250304597-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2025-10-02 US disclosed
US-5068237-A Substituted furans and derivatives thereof acting at muscarinic receptors WARNER-LAMBERT COMPANY (US) 1991-11-26 US disclosed
CN-1012365-B 2- (N-substituted guanidino) -4-heteroaryl thiazole antiulcer agent and its preparation method PFIZER (US) 1991-04-17 CN disclosed
US-4814343-A ANTIISCHEMIC U C B, S.A. (BE) 1989-03-21 US disclosed
EP-0269599-A2 Substituted 1H-imidazoles U C B, S.A. (BE) 1988-06-01 EP disclosed
CN-85103265-A The method of preparation 2-(guanidine radicals that N-replaces)-4-heteroaryl thiazole anti ulcer agent 1986-12-10 CN disclosed